BRPI0402223A - Composição farmacêutica estável de cloridrato de dilitiazem para aplicação cutânea e processo para a sua preparação - Google Patents

Composição farmacêutica estável de cloridrato de dilitiazem para aplicação cutânea e processo para a sua preparação

Info

Publication number
BRPI0402223A
BRPI0402223A BR0402223-8A BRPI0402223A BRPI0402223A BR PI0402223 A BRPI0402223 A BR PI0402223A BR PI0402223 A BRPI0402223 A BR PI0402223A BR PI0402223 A BRPI0402223 A BR PI0402223A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
stable pharmaceutical
hydrochloride
dilitiazem
Prior art date
Application number
BR0402223-8A
Other languages
English (en)
Inventor
Alexandre Miguel Veiga A Rocha
Isabel Maria Castro De Abreu
Original Assignee
Tecnimede Sociedade Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal Sa filed Critical Tecnimede Sociedade Tecnico Medicinal Sa
Publication of BRPI0402223A publication Critical patent/BRPI0402223A/pt
Publication of BRPI0402223B1 publication Critical patent/BRPI0402223B1/pt
Publication of BRPI0402223B8 publication Critical patent/BRPI0402223B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ESTáVEL DE CLORIDRATO DE DILTIAZEM PARA APLICAçãO CUTâNEA E PROCESSO PARA A SUA PREPARAçãO". A presente invenção refere-se a uma composição farmacêutica estável de cloridrato de diltiazem para aplicação cutânea, contendo um teor de desacetildiltiazem inferior a 0,3 % (m/m) , bem como a um processo para a sua preparação.
BRPI0402223A 2003-09-18 2004-06-15 composição farmacêutica de cloridrato de diltiazem e seu processo de preparação BRPI0402223B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03398006A EP1516622B1 (en) 2003-09-18 2003-09-18 Stable diltiazem hydrochloride pharmaceutical composition for cutaneous application and process for the preparation thereof

Publications (3)

Publication Number Publication Date
BRPI0402223A true BRPI0402223A (pt) 2005-06-07
BRPI0402223B1 BRPI0402223B1 (pt) 2016-10-25
BRPI0402223B8 BRPI0402223B8 (pt) 2021-05-25

Family

ID=34178675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0402223A BRPI0402223B8 (pt) 2003-09-18 2004-06-15 composição farmacêutica de cloridrato de diltiazem e seu processo de preparação

Country Status (8)

Country Link
EP (1) EP1516622B1 (pt)
AT (1) ATE376424T1 (pt)
BR (1) BRPI0402223B8 (pt)
DE (1) DE60317063T2 (pt)
ES (1) ES2297111T3 (pt)
MA (1) MA27106A1 (pt)
PT (1) PT1516622E (pt)
TN (1) TNSN04150A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022032A2 (en) * 2006-08-11 2008-02-21 Solvay Pharmaceuticals, Inc. Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same
US10960011B2 (en) 2016-06-23 2021-03-30 Servicio Andaluz De Salud Compositions for the treatment of ischemic ulcers and stretch marks
CN115337258B (zh) * 2022-07-22 2024-10-15 上海奥全生物医药科技有限公司 一种盐酸地尔硫卓的药物组合物、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
CA2089003C (en) * 1990-08-13 2001-03-20 David W. Yesair Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물

Also Published As

Publication number Publication date
ES2297111T3 (es) 2008-05-01
TNSN04150A1 (fr) 2007-03-12
BRPI0402223B1 (pt) 2016-10-25
BRPI0402223B8 (pt) 2021-05-25
EP1516622A1 (en) 2005-03-23
EP1516622B1 (en) 2007-10-24
ATE376424T1 (de) 2007-11-15
DE60317063T2 (de) 2008-08-07
PT1516622E (pt) 2008-02-04
MA27106A1 (fr) 2004-12-20
DE60317063D1 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
GEP20074197B (en) 5ht2c receptor modulators
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
BR0313555A (pt) Aplicação de inibidores de ikb-cinase na terapia da dor
BR0114927A (pt) Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BR0207726A (pt) Sais farmacêuticos
CL2003002611A1 (es) Compuestos derivados del acido tiofeno hidroxamico, 2-hidroxamida-5-[(aril o heteroaril)-disutituido-metil]-amida del acido tiofeno-2,5-dicarboxilico enantiomeros, composicion farmaceutica, procedimiento de preparacion, y su uso para el tratamiento d
BR0210139A (pt) Composições farmacêuticas
SE0301653D0 (sv) Novel compounds
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
PT1414816E (pt) Polimorfo estavel da flibanserina, processo tecnico para a sua preparacao e sua utilizacao na preparacao de medicamentos
BRPI0506449A (pt) utilização de espilantol e processo de tratamento cosmético de rugas
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
DK1465641T3 (da) Lægemidler indeholdende deuterium til behandling af sukkersyge
UA101996C2 (ru) Соединение, которое содержит интерлейкин-1 и пептид
WO2004039326A3 (en) Propofol with cysteine
BR0315836A (pt) Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: TECNIMEDE - SOCIEDADE TECNICO-MEDICINAL, S.A. (PT)

Free format text: ENDERECO ALTERADO CONFORME PET. NO 020100050512-RJ, DE 07/06/2010.

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 17 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/06 , A61K 31/554 , A61P 9/08

Ipc: A61K 31/554 (2006.01), A61K 47/00 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.